A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Genome Research

• Publication date

  2012-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/gr.133645.111PMID 22194472PMCID PMC3290779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lung cancer in never smokers--a review.

  2012cited by this paper
• CD44-SLC1A2 Gene Fusions in Gastric Cancer

  2011cited by this paper
• Lung cancer in never smokers: change of a mindset in the molecular era.

  2011cited by this paper
• Extensive genomic and transcriptional diversity identified through massively parallel DNA and RNA sequencing of eighteen Korean individuals

  2011influential reference
• Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

  2011cited by this paper
• Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples

  2011cited by this paper
• New driver mutations in non-small-cell lung cancer.

  2011cited by this paper
• Kinesins and protein kinases: key players in the regulation of microtubule dynamics and organization.

  2011cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010influential reference
• Formation of a G-quadruplex at the BCL2 major breakpoint region of the t(14;18) translocation in follicular lymphoma

  2010cited by this paper
• c-RET Molecule in Malignant Melanoma from Oncogenic RET-Carrying Transgenic Mice and Human Cell Lines

  2010cited by this paper
• A map of human genome variation from population-scale sequencing

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Does large scale DNA sequencing of patient and tumor DNA yet provide clinically actionable information?

  2010influential reference
• Expanded roles of the Fanconi anemia pathway in preserving genomic stability.

  2010cited by this paper
• Fast and SNP-tolerant detection of complex variants and splicing in short reads

  2010influential reference
• Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

  2009cited by this paper
• A highly annotated whole-genome sequence of a Korean individual

  2009cited by this paper
• The EML4‐ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild‐type EGFR and KRAS

  2009cited by this paper
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper
• A Microhomology-Mediated Break-Induced Replication Model for the Origin of Human Copy Number Variation

  2009cited by this paper
• Complex human chromosomal and genomic rearrangements.

  2009cited by this paper
• Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

  2009cited by this paper
• Protein structure prediction on the Web: a case study using the Phyre server

  2009cited by this paper
• The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer.

  2008cited by this paper
• Mapping and quantifying mammalian transcriptomes by RNA-Seq

  2008cited by this paper
• The Relationship between Over-expression of Glial Cell-derived Neurotrophic Factor and Its RET Receptor with Progression and Prognosis of Human Pancreatic Cancer

  2008cited by this paper
• Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007influential reference
• Lung cancer in never smokers: a review.

  2007cited by this paper
• Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

  2006cited by this paper
• Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity.

  2006cited by this paper
• Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia

  2006cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• RET and NTRK1 proto‐oncogenes in human diseases

  2003influential reference
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Large-scale analysis of the human and mouse transcriptomes

  2002influential reference
• Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.

  2000cited by this paper
• Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer.

  1998cited by this paper
• Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene.

  1996cited by this paper
• GDNF signalling through the Ret receptor tyrosine kinase

  1996cited by this paper
• Activation of a novel human transforming gene, ret, by DNA rearrangement.

  1985cited by this paper

• Rearranged during transfection (RET) lung cancer - Update on targeted therapies.

  2025cites this paper
• Accurate RET Fusion Detection in Solid Tumors Using RNA Sequencing Coverage Imbalance Analysis

  2025cites this paper
• AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors

  2025cites this paper
• Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer

  2025cites this paper
• Personalized Approaches to Lung Cancer Treatment: A Review of Targeted Therapies, Pharmacogenomics, and Combination Strategies

  2025cites this paper
• Overcoming resistance in RET-altered cancers through rational inhibitor design and combination therapies.

  2025cites this paper
• Rearranged During Transfection Rearrangement Detection by Fluorescence In Situ Hybridization Compared With Other Techniques in NSCLC

  2024cites this paper
• The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions

  2024cites this paper
• Pathogenicity Prediction of Gene Fusion in Structural Variations: A Knowledge Graph-Infused Explainable Artificial Intelligence (XAI) Framework

  2024cites this paper
• Targeting RET alterations in non-small cell lung cancer.

  2024cites this paper
• Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer

  2024cites this paper
• The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

  2024cites this paper
• Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: “Shadows and Fogs”

  2024cites this paper
• A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol

  2024cites this paper
• The rapidly changing field of predictive biomarkers of non-small cell lung cancer

  2024cites this paper
• RET Fusion Testing in Patients With NSCLC: The RETING Study

  2024influential citation
• LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC

  2024cites this paper
• Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.

  2024cites this paper
• Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

  2024cites this paper
• Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data

  2024cites this paper
• An Ensemble AI Model for RET Alteration Detection Using H&E Images as a Putative Screening Tool for More Efficient Genomic Alteration Detection

  2024cites this paper
• A whole-genome reference panel of 14,393 individuals for East Asian populations accelerates discovery of rare functional variants

  2023cites this paper
• Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.

  2023cites this paper
• RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity

  2023cites this paper
• Current landscape and future prospects of RET and ROS1 targets.

  2023cites this paper
• Progress and challenges in RET-targeted cancer therapy

  2023cites this paper
• RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape

  2023cites this paper
• FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusion.

  2023cites this paper
• Genome-wide Detection of Chimeric Transcripts in Early-stage Non-small Cell Lung Cancer

  2023cites this paper
• RET receptor signaling: Function in development, metabolic disease, and cancer

  2022cites this paper
• A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report

  2022cites this paper
• Precious Gene: The Application of RET-Altered Inhibitors

  2022cites this paper
• Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report

  2022cites this paper
• Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer.

  2022cites this paper
• Whole-genome Sequencing-based Lung Cancer Precision Medicine in Japan

  2022cites this paper
• Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing

  2022cites this paper
• RET signaling pathway and RET inhibitors in human cancer

  2022cites this paper
• The role of next-generation sequencing in detecting gene FUSIONS with KNOWN and UNKNOWN partners: A single-center experience with methodologies' integration.

  2022cites this paper
• Drosophila melanogaster: A platform for anticancer drug discovery and personalized therapies

  2022cites this paper
• RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.

  2022cites this paper
• Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

  2022cites this paper
• Advances in the treatment of RET-fusion-positive lung cancer.

  2021cites this paper
• RET Inhibitors in Non-Small-Cell Lung Cancer

  2021cites this paper
• Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review

  2021influential citation
• Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.

  2021cites this paper
• miR-30c-1 encourages human corneal endothelial cells to regenerate through ameliorating senescence

  2021cites this paper
• RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer.

  2021cites this paper
• Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation

  2021cites this paper
• The rising challenge of oncogene addiction in lung cancer.

  2021cites this paper
• p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics

  2021cites this paper
• Discovery of a Potent Candidate for RET-Specific Non-Small-Cell Lung Cancer—A Combined In Silico and In Vitro Strategy

  2021cites this paper
• An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology

  2021cites this paper
• The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients

  2021cites this paper
• Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.

  2021cites this paper
• Breakthrough in targeted therapy for non-small cell lung cancer.

  2021cites this paper
• OLFM4-RET fusion is an oncogenic driver in small intestine adenocarcinoma

  2021cites this paper
• Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives

  2021cites this paper
• Identification of RET fusions in a Chinese multicancer retrospective analysis by next‐generation sequencing

  2021cites this paper
• RET融合阳性晚期非小细胞肺癌治疗进展

  2021cites this paper
• Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report

  2021cites this paper
• A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling

  2021cites this paper
• Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives.

  2021cites this paper
• Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer

  2021cites this paper
• Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity

  2021cites this paper
• OTT_A_313896 3739..3744

  2021cites this paper
• Analytical Accuracy of RET Fusion Detection by Break-Apart Fluorescence In Situ Hybridization.

  2021cites this paper
• The role of multidisciplinary team and molecular tumor board in the treatment of a patient with lung cancer.

  2021cites this paper
• A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report

  2021cites this paper
• Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

  2021cites this paper
• Identifying common transcriptome signatures of cancer by interpreting deep learning models

  2021cites this paper
• Engineering chromosome rearrangements in cancer

  2021cites this paper
• Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.

  2020cites this paper
• Identifying novel oncogenic RET mutations and characterising their sensitivity to RET-specific inhibitors

  2020cites this paper
• New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

  2020cites this paper
• Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

  2020cites this paper
• Genetics of Lung Cancer

  2020cites this paper
• Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.

  2020cites this paper
• RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation

  2020cites this paper
• State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

  2020cites this paper
• Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.

  2020cites this paper
• Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives

  2020cites this paper
• Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with RET Rearrangements

  2020cites this paper
• Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers

  2020cites this paper
• Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)

  2020cites this paper
• Personalized Management of Cancers of Various Organs/Systems

  2020cites this paper
• Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer.

  2020cites this paper
• A fusion of CD63–BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis

  2020cites this paper
• Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing.

  2020cites this paper
• Decade in review: a new era for RET-rearranged lung cancers

  2020cites this paper
• Exploring Molecular Docking algorithm for Lung Cancer Drug Discovery – A Case Study with RET Protein

  2020influential citation
• Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.

  2020cites this paper
• Molecular and Biological Basis of Lung Cancer-Part I

  2020influential citation
• Molecular Profiling of Afatinib-Resistant Non-Small Cell Lung Cancer Cells in vivo Derived from Mice.

  2020cites this paper
• Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough.

  2020cites this paper
• Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer

  2020cites this paper
• RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer

  2020cites this paper
• Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

  2020cites this paper
• Pathology, Biomarkers, and Molecular Diagnostics

  2020cites this paper
• The Next Target for NSCLC: Let It Be "RET".

  2020cites this paper
• A fusion of CD63–BCAR4 identified in lung adenocarcinoma promotes tumorigenicity and metastasis

  2020cites this paper